+91-9555505981
[email protected]
ARRAYMATIC
Home
Services
Industries
About Us
Hire Developers
Get Quote
ARRAYMATIC

ArrayMatic Technologies

B-23, B Block, Sector 63, Noida, Uttar Pradesh 201301

[email protected]

+91-9555505981

Discover

About UsTechnologyCase StudiesHire DevelopersGet Quote

Services

AI & Machine LearningBlockchain DevelopmentWeb DevelopmentMobile App DevelopmentCloud & DevOpsData & IoT Solutions

Social

FacebookTwitterInstagramLinkedin

Technologies we use

React
Next.js
Node.js
Python
All technologies

© 2026, ArrayMatic Technologies

Privacy PolicyTerms of ServiceCookie Policy
HomeIndustriesHealthcareDrug Discovery & Development with AI

Healthcare

Drug Discovery & Development with AI

Computational biology and ML systems that accelerate target identification, compound screening, and trial cohort selection — reducing the time and cost of early-stage drug development.

Discuss your projectSee our work

0h

Response time

0+

Projects delivered

0+

Years in production

Industry overview

AI systems for pharmaceutical drug discovery that accelerate target identification, virtual compound screening, ADMET property prediction, and clinical trial cohort selection — compressing the timeline of early-stage development.

At a glance

  • Target and pathway identification from genomic and literature data
  • Virtual compound screening against target molecular structures
  • ADMET property prediction for early toxicity and efficacy assessment

Drug discovery is one of the most expensive and time-consuming processes in any industry — a new molecule takes an average of 12 years and over $2 billion to reach approval. The early stages — target identification, lead compound selection, and optimisation — are data-intensive processes where AI can compress timelines significantly by evaluating far more candidates computationally than wet lab processes can test physically.

What we build

We build target identification systems that mine genomic, proteomic, and clinical literature data to propose novel disease targets. Virtual screening pipelines evaluate molecular libraries against target structures computationally, ranking candidates by predicted binding affinity before expensive synthesis. ADMET prediction models assess absorption, distribution, metabolism, excretion, and toxicity properties early — eliminating compounds that would fail in vivo before resources are committed. Clinical trial cohort selection tools identify eligible patients from EHR data to accelerate trial recruitment.

Key capabilities

What we deliver

Engagements are scoped to your business context — these are the core capabilities we bring to healthcare clients.

Target and pathway identification from genomic and literature data

Virtual compound screening against target molecular structures

ADMET property prediction for early toxicity and efficacy assessment

Clinical trial cohort identification from EHR population data

Scientific literature mining and hypothesis generation

Regulatory submission data preparation and documentation support

Built with

React NativeAWSNode.jsPostgreSQL

Work with us

Ready to start a project?

Share what you're building — we'll respond within one business day with questions or a proposal outline.

Get a quoteSee our work